GeneDx Holdings Corp. Class A Common Stock WGS
i
Market dataready · fetched 2026-11-07T07:28:49.166Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:46:28.907218266Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-07T07:28:48.760739+00:00
GeneDx Holdings Corp. Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 83.95 | 219.0% | 36.7% | 50.43 | 240.3% | 23.9% |
| 25Δ | 78.63 | 206.2% | 28.9% | 53.38 | 238.0% | 20.5% |
| 30Δ | 74.53 | 199.2% | 23.1% | 56.15 | 232.0% | 17.2% |
| 35Δ | 71.99 | 206.1% | 20.1% | 58.56 | 228.2% | 14.9% |
| 40Δ | 70.07 | 217.9% | 18.5% | 60.83 | 219.6% | 12.6% |
| 45Δ | 67.47 | 213.3% | 15.5% | 63.11 | 223.4% | 11.1% |
| 50Δ | 64.90 | 200.5% | 12.2% | 65.51 | 227.0% | 9.7% |
| 55Δ | 62.86 | 203.1% | 10.5% | 67.96 | 227.2% | 8.3% |
| 60Δ | 60.82 | 213.6% | 9.3% | 70.51 | 226.7% | 7.0% |
| 65Δ | 58.61 | 219.6% | 7.9% | 73.24 | 223.9% | 5.8% |
| 70Δ | 56.31 | 222.2% | 6.4% | 76.29 | 216.6% | 4.7% |
| 75Δ | 53.78 | 226.8% | 5.2% | 80.05 | 220.1% | 3.7% |
| 80Δ | 51.25 | 217.9% | 3.8% | 84.31 | 221.7% | 2.8% |
20Δ
- Pseudo strike
- 83.95
- IV
- 219.0%
- B/E move
- 36.7%
- Pseudo strike
- 50.43
- IV
- 240.3%
- B/E move
- 23.9%
25Δ
- Pseudo strike
- 78.63
- IV
- 206.2%
- B/E move
- 28.9%
- Pseudo strike
- 53.38
- IV
- 238.0%
- B/E move
- 20.5%
30Δ
- Pseudo strike
- 74.53
- IV
- 199.2%
- B/E move
- 23.1%
- Pseudo strike
- 56.15
- IV
- 232.0%
- B/E move
- 17.2%
35Δ
- Pseudo strike
- 71.99
- IV
- 206.1%
- B/E move
- 20.1%
- Pseudo strike
- 58.56
- IV
- 228.2%
- B/E move
- 14.9%
40Δ
- Pseudo strike
- 70.07
- IV
- 217.9%
- B/E move
- 18.5%
- Pseudo strike
- 60.83
- IV
- 219.6%
- B/E move
- 12.6%
45Δ
- Pseudo strike
- 67.47
- IV
- 213.3%
- B/E move
- 15.5%
- Pseudo strike
- 63.11
- IV
- 223.4%
- B/E move
- 11.1%
50Δ
- Pseudo strike
- 64.90
- IV
- 200.5%
- B/E move
- 12.2%
- Pseudo strike
- 65.51
- IV
- 227.0%
- B/E move
- 9.7%
55Δ
- Pseudo strike
- 62.86
- IV
- 203.1%
- B/E move
- 10.5%
- Pseudo strike
- 67.96
- IV
- 227.2%
- B/E move
- 8.3%
60Δ
- Pseudo strike
- 60.82
- IV
- 213.6%
- B/E move
- 9.3%
- Pseudo strike
- 70.51
- IV
- 226.7%
- B/E move
- 7.0%
65Δ
- Pseudo strike
- 58.61
- IV
- 219.6%
- B/E move
- 7.9%
- Pseudo strike
- 73.24
- IV
- 223.9%
- B/E move
- 5.8%
70Δ
- Pseudo strike
- 56.31
- IV
- 222.2%
- B/E move
- 6.4%
- Pseudo strike
- 76.29
- IV
- 216.6%
- B/E move
- 4.7%
75Δ
- Pseudo strike
- 53.78
- IV
- 226.8%
- B/E move
- 5.2%
- Pseudo strike
- 80.05
- IV
- 220.1%
- B/E move
- 3.7%
80Δ
- Pseudo strike
- 51.25
- IV
- 217.9%
- B/E move
- 3.8%
- Pseudo strike
- 84.31
- IV
- 221.7%
- B/E move
- 2.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 76.57% | |
| 76.36% | |
| 75.97% | |
| 81.02% | |
| 65.96% | |
| 68.20% | |
| 68.45% | |
| 66.10% | |
| 76.28% | |
| 62.95% | |
| 70.82% | |
| 68.84% | |
| 69.82% | |
| 66.73% | |
| 62.37% | |
| 61.14% | |
| 64.84% | |
| 65.27% | |
| 67.23% | |
| 60.83% | |
| 69.66% | |
| 71.42% | |
| 75.38% | |
| 63.24% | |
| 66.57% | |
| 66.73% | |
| 69.93% | |
| 68.08% | |
| 63.50% | |
| 68.24% | |
| 71.06% | |
| 75.08% | |
| 79.02% | |
| 70.66% | |
| 76.00% | |
| 76.31% | |
| 83.07% | |
| 92.75% | |
| 82.16% | |
| 90.97% | |
| 92.50% | |
| 94.54% | |
| 89.60% | |
| 94.72% | |
| 99.04% | |
| 99.15% | |
| 104.54% | |
| 109.38% | |
| 119.79% | |
| 126.41% | |
| 133.15% | |
| 140.76% | |
| 153.97% | |
| 175.18% | |
| 138.90% | |
| 142.11% | |
| 138.08% | |
| 144.87% | |
| 160.84% |
Diagnostics & Research
XGN
Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The…
More →A
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global…
More →ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is…
More →BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
More →CDNA
Description unavailable
More →CRL
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell…
More →